Harmony Biosciences Holdings, Inc. (HRMY): who owns it and who trades it
As of Nov 16, 2026, HRMY insiders reported 13 open-market sales worth $6M and no purchases in the last 12 months, with 48% of the sale value made under pre-set 10b5-1 plans. The largest seller was Kumar Budur (CHIEF MEDICAL OFFICER), with $3.1M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Harmony Biosciences Holdings
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns HRMY
327 funds and institutions reported HRMY shares worth $2B at the end of Q2 2026, about 98% of the company. The largest holder is BlackRock, Inc. with 12.3%.
Funds and institutions (13F) 98%Everyone else 2%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 7.10M | 12.27% | $259M | +0% |
| FMR LLC (Fidelity) | 3.57M | 6.17% | $130M | +13% |
| Vanguard Portfolio Management LLC | 2.88M | 4.98% | $105M | +6% |
| American Century Companies Inc | 2.54M | 4.39% | $92.5M | +21% |
| Dimensional Fund Advisors LP | 2.39M | 4.13% | $87.1M | +15% |
| Vanguard Capital Management LLC | 2.11M | 3.64% | $76.6M | +0% |
| Lsv Asset Management | 2.06M | 3.56% | $75M | +2% |
| California State Teachers Retirement System | 2.06M | 3.56% | $56.6M | – |
| State Street Corp | 1.86M | 3.21% | $67.7M | +4% |
| Armistice Capital, LLC | 1.56M | 2.70% | $56.9M | -4% |
| Geode Capital Management, LLC | 1.44M | 2.49% | $52.5M | +9% |
| Arrowstreet Capital, Limited Partnership | 1.31M | 2.27% | $47.8M | -5% |
| Renaissance Technologies LLC | 1.20M | 2.06% | $43.5M | +11% |
| Two Sigma Investments, LP | 959,136 | 1.66% | $34.9M | +31% |
| AQR Capital Management LLC | 934,326 | 1.61% | $34M | +30% |
| SG Americas Securities, LLC | 882,720 | 1.52% | $32.1M | -56% |
| Valor Management LLC | 818,013 | 1.41% | $29.8M | +598% |
| Morgan Stanley | 733,684 | 1.27% | $26.7M | -29% |
| UBS Group AG | 602,990 | 1.04% | $22M | +35% |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | 551,075 | 0.95% | $20.1M | -3% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, HRMY insiders reported $0 of open-market purchases and $6M of sales. 48% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | Kumar Budur | CHIEF MEDICAL OFFICER | Sale | 35,852 | $43.05 | $1.5M | Form 4 |
| Sep 17, 2026 | Kumar Budur | CHIEF MEDICAL OFFICER | Sale | 800 | $43.00 | $34.4K | Form 4 |
| Sep 16, 2026 | Kumar Budur | CHIEF MEDICAL OFFICER | Sale | 1,800 | $43.01 | $77.4K | Form 4 |
| Sep 8, 2026 | Kumar Budur | CHIEF MEDICAL OFFICER | Sale | 22,954 | $43.10 | $989K | Form 4 |
| Sep 8, 2026 | Kumar Budur | CHIEF MEDICAL OFFICER | Sale | 1,000 | $42.79 | $42.8K | Form 4 |
| Sep 8, 2026 | Kumar Budur | CHIEF MEDICAL OFFICER | Sale | 4,500 | $42.25 | $190K | Form 4 |
| Sep 4, 2026 | Kumar Budur | CHIEF MEDICAL OFFICER | Sale | 5,500 | $41.98 | $231K | Form 4 |
| Jan 26, 2026 | Sandip Kapadia | CFO | Sale plan | 3,746 | $37.15 | $139K | Form 4 |
| Jan 15, 2026 | Sandip Kapadia | CFO | Sale plan | 20,961 | $35.92 | $753K | Form 4 |
| Dec 12, 2025 | Jeffrey M. Dayno | CEO | Sale plan | 5,933 | $40.11 | $238K | Form 4 |
| Dec 12, 2025 | Jeffrey M. Dayno | CEO | Sale plan | 20,000 | $40.11 | $802K | Form 4 |
| Dec 5, 2025 | Sandip Kapadia | CFO | Sale plan | 20,000 | $39.54 | $791K | Form 4 |
| Nov 21, 2025 | Sandip Kapadia | CFO | Sale plan | 3,427 | $35.00 | $120K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Kumar Budur | CHIEF MEDICAL OFFICER | – | $3.1M | Sep 18, 2026 |
| Sandip Kapadia | CHIEF FINANCIAL OFFICER | – | $1.8M | Jan 26, 2026 |
| Jeffrey M. Dayno | PRESIDENT, CEO, Director | – | $1M | Dec 12, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
HRMY short interest
High short interest. 11.4% of HRMY shares are sold short: about 1 share in 9. Over the last 12 reports the number of shares short went up 1%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 6.66M HRMY shares were sold short, 11.4% of the shares outstanding, up 23.1% from the report before. At the average daily volume of 1.18M shares, buying them all back would take about 5.6 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 6.66M | 11.44% | +23% | 1.18M | 5.6 |
| Oct 15, 2026 | 5.41M | 9.30% | -2% | 876,105 | 6.2 |
| Sep 30, 2026 | 5.53M | 9.50% | +20% | 1.11M | 5.0 |
| Sep 15, 2026 | 4.63M | 7.95% | -10% | 1.07M | 4.3 |
| Aug 31, 2026 | 5.16M | 8.87% | +25% | 566,650 | 9.1 |
| Aug 14, 2026 | 4.14M | 7.10% | -8% | 866,805 | 4.8 |
| Jul 31, 2026 | 4.50M | 7.72% | -12% | 889,701 | 5.0 |
| Jul 15, 2026 | 5.11M | 8.84% | +11% | 754,093 | 6.8 |
| Jun 30, 2026 | 4.61M | 7.97% | -1% | 809,566 | 5.7 |
| Jun 15, 2026 | 4.65M | 8.02% | -22% | 894,751 | 5.2 |
| May 29, 2026 | 5.94M | 10.26% | -10% | 689,110 | 8.6 |
| May 15, 2026 | 6.62M | 11.43% | -4% | 805,911 | 8.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Harmony Biosciences Holdings company events
Harmony Biosciences Holdings filed 11 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Oct 30, 2026LeadershipAmended an earlier report. Of the Current Report on Form 8-K filed by Harmony Biosciences Holdings, Inc. on October 13, 2026. Filing
- Oct 13, 2026LeadershipHarmony Biosciences Holdings, Inc. announced that Jeffrey M. Dayno, M.D., as part of a leadership succession plan, will be retiring as the Company’s President and Chief Executive Officer and stepping down as a Class I director of the Company’s Board of Directors, in each case, effective as of… Filing
- Aug 4, 2026ResultsReleased financial results. Filing
- Jul 16, 2026LeadershipThe Company announced that Glenn Reicin, the Company’s Chief Financial Officer, will be stepping down as the Company’s Chief Financial Officer effective as of July 16, 2026 to pursue other career opportunities. In connection with his departure from the Company, on July 16, 2026, the Company and… Filing
- May 14, 2026VoteReported shareholder vote results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 14, 2026LeadershipHarmony Biosciences Holdings, Inc. announced that Sandip Kapadia, the Company’s Chief Financial Officer, will be stepping down as the Company’s Chief Financial Officer effective as of April 14, 2026 to pursue other career opportunities. Filing
- Apr 2, 2026LeadershipHarmony Biosciences Holdings, Inc. named Peter Anastasiou the Company’s Senior Executive Vice President and Chief Operating Officer, effective April 2, 2026. Filing
- Feb 24, 2026ResultsReleased financial results. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Harmony Biosciences Holdings financials
Famous investors that hold HRMY
4 of the 50 well-known investors we track reported holding HRMY in their latest 13F filing. The largest position is Jim Simons's, worth $54.9M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 1.40M | $54.9M | 0.1% | +17% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 270,269 | $10.6M | 0.0% | +9% |
| Israel Englander · Millennium Management | Q3 2026 | 20,952 | $823K | 0.0% | -93% |
| Jeremy Grantham · GMO | Q3 2026 | 12,970 | $509K | 0.0% | +19% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named HRMY in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 12.6% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 12.6% |
Questions about Harmony Biosciences Holdings, Inc. (HRMY) stock
Who owns the most HRMY stock?
The largest reported owner of Harmony Biosciences Holdings, Inc. (HRMY) is BlackRock, Inc., with 12.3% of the company. In total, 327 funds and institutions reported holding HRMY at the end of Q2 2026, together about 98% of the shares. See the largest owners.
Are HRMY insiders buying or selling?
In the last 12 months, HRMY insiders reported no open-market purchases and 13 sales worth $6M. The latest trade was on Sep 18, 2026. See every trade.
What is the short interest in HRMY?
As of Oct 30, 2026, 6.66M HRMY shares were sold short, 11.4% of the shares outstanding, up 23.1% from the report before. At the average daily volume of 1.18M shares, buying them all back would take about 5.6 trading days (days to cover). See the history.
Which famous investors hold HRMY?
4 of the 50 well-known investors we track reported HRMY in their latest 13F filing, including Jim Simons, Ray Dalio, Israel Englander. The largest position is worth $54.9M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.